Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients With Solid Cancers (PROGNOSIS-RCT)
Primary Purpose
Frailty, Cancer, Age
Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Comprehensive Geriatric Assessment and follow-up
Sponsored by
About this trial
This is an interventional treatment trial for Frailty focused on measuring Frailty, Aged, Neoplasms, Cancer Patients, Geriatric Screening, Geriatric 8, Geriatric Assessment, Randomized Clinical Trial
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 70 years
- Living in the region of Southern Denmark
- Newly diagnosed solid tumours assessed eligible for antineoplastic treatment
- Vulnerable or frail (G8 ≤ 14)
Exclusion Criteria:
- Inability to speak or understand Danish
- Inability to give informed consent
- Already consulting geriatric outpatient clinic
- Already receiving active treatment for other coexisting solid tumours, haematologic cancers, or non-melanoma skin cancer or has received oncologic treatment the past year
Sites / Locations
- Odense University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention
Control
Arm Description
Comprehensive Geriatric Assessment and follow-up as add on to standard oncologic care
standard oncologic care according to national guidelines
Outcomes
Primary Outcome Measures
physical function for patients receiving palliative oncologic treatment
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
unplanned hospital admissions for patients receiving adjuvant oncologic treatment
number of unplanned hospitalisations including admissions to Oncologic Department, Emergency Department and Medical Departments. Data will be retrieved trough review of electronic medical records.
Secondary Outcome Measures
Physical functional for patients receiving curative oncologic treatment
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
Physical functional for patients receiving curative oncologic treatment
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
Physical functional for patients receiving palliative oncologic treatment
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
number of unplanned hospital admissions for patients receiving palliative oncologic treatment
Number of unplanned hospitalisations including admissions to Oncologic Department, Emergency Department and Medical Departments. Data will be retrieved trough review of electronic medical records.
Health-related Quality of life
Measured by EORTC-QLQ-C30
Health-related Quality of life
Measured by EORTC-QLQ-ELD14
Elderly Functional Index Score (ELFI-score)
Self reported functioning score. It is a composite score derived from the three scales "physical functioning", "Role functioning" and Social Functioning", from the quality of life questionnaire EORTC-QLQ-C30 and the scale "Mobility" from the quality of life questionnaire EORTC-QLQ-ELD-14. The range is (12-48), with a higher score being a better outcome.
Number of patients who experience oncologic treatment toxicity
Treatment toxicity grade 3+ evaluated with Common Terminology Criteria for Adverse Events
Number of patients with adherence to initial oncologic treatment plan
Registration of dose reductions, discontinuations and delays of intended cancer treatment.
Degree of Polypharmacy (PP)
Degree of polypharmacy. Polypharmacy is defined as daily use of more than 5 prescription drugs.
Number of potential Inappropriate Medications (PIM)
Using the Screening Tool for Older Persons Prescriptions (STOPP) criteria. Number of PIM will be registered for each patient
Number of Potential Drug Interactions (PDI)
Using Stockley's Drug Interaction Database. Number of PDI will be registered for each patient
Overall survival
Measured from Geriatric 8 screening to time of death
Cancer specific survival
Measured from Geriatric 8 screening to time of death in patients with residual cancer
Full Information
NCT ID
NCT04686851
First Posted
October 26, 2020
Last Updated
March 28, 2023
Sponsor
Odense University Hospital
Collaborators
University of Southern Denmark, Danish Cancer Society, Academy of Geriatric Cancer, Odense Patient Data Explorative Network, Region of Southern Denmark
1. Study Identification
Unique Protocol Identification Number
NCT04686851
Brief Title
Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients With Solid Cancers
Acronym
PROGNOSIS-RCT
Official Title
Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients With Solid Cancers (PROGNOSIS-RCT)
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2020 (Actual)
Primary Completion Date
November 1, 2023 (Anticipated)
Study Completion Date
June 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Odense University Hospital
Collaborators
University of Southern Denmark, Danish Cancer Society, Academy of Geriatric Cancer, Odense Patient Data Explorative Network, Region of Southern Denmark
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A Randomized Clinical Trial examining the effects of Comprehensive Geriatric Assessment as an add on to oncologic treatment. Participants included are cancer patients found eligible for oncologic treatment, age 70 or more, and screened frail with the Geriatric 8 screening tool.
Detailed Description
This study aims to examine the effects of Comprehensive Geriatric Assessment and interventions on prognosis in the older frail cancer patient in a Randomized Clinical Trial design.
Patients screened frail with the Geriatric 8 screening tool, aged 70 or more, and found eligible for oncologic treatment, will be included. We plan to enrol a total of 322 cancer patients for 12 months. Participants will be allocated randomly to either interventional or control group.
Participants in the interventional group will be offered a Comprehensive Geriatric Assessment and intervention at the start-up of cancer treatment. The Comprehensive Geriatric Assessment will be an add on to standardized cancer treatment offered at the Oncologic Outpatient Clinic at Odense University Hospital.
Comprehensive Geriatric Assessment will be performed by a team consisting of a doctor, nurse and physiotherapist. If needed, referral to a dietician or an occupational therapist for further evaluation will be made. The health issues are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). Follow-up on Comprehensive Geriatric Assessment is scheduled for one month after initial evaluation.
The randomized groups will be compared with respect to primary and secondary endpoints.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frailty, Cancer, Age
Keywords
Frailty, Aged, Neoplasms, Cancer Patients, Geriatric Screening, Geriatric 8, Geriatric Assessment, Randomized Clinical Trial
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Clinical Trial with 2 randomized 1:1 parallel study groups
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
322 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Comprehensive Geriatric Assessment and follow-up as add on to standard oncologic care
Arm Title
Control
Arm Type
No Intervention
Arm Description
standard oncologic care according to national guidelines
Intervention Type
Other
Intervention Name(s)
Comprehensive Geriatric Assessment and follow-up
Intervention Description
All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.
Follow-up on initial treatment plan is scheduled to one month after baseline CGA.
Primary Outcome Measure Information:
Title
physical function for patients receiving palliative oncologic treatment
Description
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
Time Frame
3 months
Title
unplanned hospital admissions for patients receiving adjuvant oncologic treatment
Description
number of unplanned hospitalisations including admissions to Oncologic Department, Emergency Department and Medical Departments. Data will be retrieved trough review of electronic medical records.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Physical functional for patients receiving curative oncologic treatment
Description
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
Time Frame
3 months
Title
Physical functional for patients receiving curative oncologic treatment
Description
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
Time Frame
6 months
Title
Physical functional for patients receiving palliative oncologic treatment
Description
measured by 30 seconds Chair Stand Test, number of repetitions in a 30 seconds time period.
Time Frame
6 months
Title
number of unplanned hospital admissions for patients receiving palliative oncologic treatment
Description
Number of unplanned hospitalisations including admissions to Oncologic Department, Emergency Department and Medical Departments. Data will be retrieved trough review of electronic medical records.
Time Frame
6 months
Title
Health-related Quality of life
Description
Measured by EORTC-QLQ-C30
Time Frame
12 months
Title
Health-related Quality of life
Description
Measured by EORTC-QLQ-ELD14
Time Frame
12 months follow-up
Title
Elderly Functional Index Score (ELFI-score)
Description
Self reported functioning score. It is a composite score derived from the three scales "physical functioning", "Role functioning" and Social Functioning", from the quality of life questionnaire EORTC-QLQ-C30 and the scale "Mobility" from the quality of life questionnaire EORTC-QLQ-ELD-14. The range is (12-48), with a higher score being a better outcome.
Time Frame
6 months
Title
Number of patients who experience oncologic treatment toxicity
Description
Treatment toxicity grade 3+ evaluated with Common Terminology Criteria for Adverse Events
Time Frame
6 months
Title
Number of patients with adherence to initial oncologic treatment plan
Description
Registration of dose reductions, discontinuations and delays of intended cancer treatment.
Time Frame
6 months
Title
Degree of Polypharmacy (PP)
Description
Degree of polypharmacy. Polypharmacy is defined as daily use of more than 5 prescription drugs.
Time Frame
3 months
Title
Number of potential Inappropriate Medications (PIM)
Description
Using the Screening Tool for Older Persons Prescriptions (STOPP) criteria. Number of PIM will be registered for each patient
Time Frame
3 months
Title
Number of Potential Drug Interactions (PDI)
Description
Using Stockley's Drug Interaction Database. Number of PDI will be registered for each patient
Time Frame
3 months
Title
Overall survival
Description
Measured from Geriatric 8 screening to time of death
Time Frame
12 months
Title
Cancer specific survival
Description
Measured from Geriatric 8 screening to time of death in patients with residual cancer
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 70 years
Living in the region of Southern Denmark
Newly diagnosed solid tumours assessed eligible for antineoplastic treatment
Vulnerable or frail (G8 ≤ 14)
Exclusion Criteria:
Inability to speak or understand Danish
Inability to give informed consent
Already consulting geriatric outpatient clinic
Already receiving active treatment for other coexisting solid tumours, haematologic cancers, or non-melanoma skin cancer or has received oncologic treatment the past year
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jesper Ryg, MD
Phone
60152610
Ext
0045
Email
Jesper.Ryg@rsyd.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ann-Kristine W Giger, MD
Organizational Affiliation
Department of Geriatric Medicine, Odense University Hospital, Odense
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Cecilia M Lund, MD, PhD
Organizational Affiliation
Department of Medicine, Herlev and Gentofte University Hospital, Copenhagen
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Per Pfeiffer, MD, PhD
Organizational Affiliation
Department of Clinical Oncology, Odense University Hospital, Odense
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Trine L Jørgensen, MD, PhD
Organizational Affiliation
Department of Clinical Oncology, Odense University Hospital, Odense
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Marianne Ewertz, MD, DMSc
Organizational Affiliation
Institute of Clinical Research, University of Southern Denmark, Odense
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Henrik Ditzel, MD, DMSc
Organizational Affiliation
Department og Geriatric Medicine, Odense University Hospital, Odense
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jesper Ryg, MD, PhD
Organizational Affiliation
Department of Geriatric Medicine, Odense University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Odense University Hospital
City
Odense
State/Province
Southern Denmark
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jesper Ryg, MD, Prof.
Phone
60152610
Ext
0045
Email
jesper.ryg@rsyd.dk
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34362713
Citation
Giger AW, Ditzel HM, Jorgensen TL, Ditzel HJ, Mohammadnejad A, Ewertz M, Pfeiffer P, Lund CM, Ryg J. Predictive value of geriatric oncology screening and geriatric assessment of older patients with cancer: A randomized clinical trial protocol (PROGNOSIS-RCT). J Geriatr Oncol. 2022 Jan;13(1):116-123. doi: 10.1016/j.jgo.2021.07.005. Epub 2021 Aug 4.
Results Reference
derived
Learn more about this trial
Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients With Solid Cancers
We'll reach out to this number within 24 hrs